AR110468A1 - Formulaciones de buprenorfina de liberación sostenida y método de tratamiento - Google Patents
Formulaciones de buprenorfina de liberación sostenida y método de tratamientoInfo
- Publication number
- AR110468A1 AR110468A1 ARP170102519A ARP170102519A AR110468A1 AR 110468 A1 AR110468 A1 AR 110468A1 AR P170102519 A ARP170102519 A AR P170102519A AR P170102519 A ARP170102519 A AR P170102519A AR 110468 A1 AR110468 A1 AR 110468A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- pharmaceutical composition
- injectable pharmaceutical
- composition according
- acyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una composición farmacéuticamente inyectable, que comprende: una solución de 3-acil-buprenorfina o una sal farmacéuticamente aceptable de la misma, en un solvente orgánico biocompatible, en donde la composición farmacéutica inyectable exhibe un perfil de liberación estable, el cual se mantiene durante una semana cuando es inyectado a un paciente o a un animal. Reivindicación 2: La composición farmacéutica inyectable de acuerdo con la reivindicación 1, en donde el grupo acilo comprende un grupo alquilcarbonilo y en donde una porción alquilo del grupo alquilcarbonilo es una cadena lineal o ramificada, que tiene 1 - 20 átomos de carbono. Reivindicación 3: La composición farmacéutica inyectable de acuerdo con la reivindicación 1, en donde el grupo acilo comprende un grupo arilcarbonilo y en donde una porción arilo del grupo arilcarbonilo es un grupo aromático que tiene 6 - 18 carbonos. Reivindicación 4: La composición farmacéutica inyectable de acuerdo con una cualquiera de las reivindicaciones 1 - 3, en donde el solvente orgánico biocompatible se selecciona entre el grupo que consiste en N-metil-2-pirrolidona, acetato de etilo, etanol, butanol, 2-butanol, isobutanol, isopropanol, glicerina, benzoato de bencilo, dimetilsulfóxido, N,N-dimetilacetamida, propilenglicol, dimetilglicol, alcohol bencílico y una combinación de dos o más de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662394168P | 2016-09-13 | 2016-09-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110468A1 true AR110468A1 (es) | 2019-04-03 |
Family
ID=61619029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102519A AR110468A1 (es) | 2016-09-13 | 2017-09-13 | Formulaciones de buprenorfina de liberación sostenida y método de tratamiento |
Country Status (30)
Country | Link |
---|---|
US (1) | US10744132B2 (es) |
EP (1) | EP3512518B1 (es) |
JP (1) | JP6929367B2 (es) |
KR (1) | KR102244500B1 (es) |
CN (1) | CN109789137B (es) |
AR (1) | AR110468A1 (es) |
AU (1) | AU2017325910B2 (es) |
BR (1) | BR112019004923A2 (es) |
CA (1) | CA3033046C (es) |
CL (1) | CL2019000624A1 (es) |
CO (1) | CO2019003632A2 (es) |
DK (1) | DK3512518T3 (es) |
ES (1) | ES2934721T3 (es) |
FI (1) | FI3512518T3 (es) |
HR (1) | HRP20230062T8 (es) |
HU (1) | HUE060906T2 (es) |
LT (1) | LT3512518T (es) |
MX (1) | MX2019002675A (es) |
MY (1) | MY196269A (es) |
PE (1) | PE20190707A1 (es) |
PH (1) | PH12019500466A1 (es) |
PL (1) | PL3512518T3 (es) |
PT (1) | PT3512518T (es) |
RS (1) | RS63894B1 (es) |
RU (1) | RU2747306C2 (es) |
SG (1) | SG11201901294QA (es) |
SI (1) | SI3512518T1 (es) |
TW (1) | TWI743193B (es) |
WO (1) | WO2018050043A1 (es) |
ZA (1) | ZA201900890B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1057075C (zh) * | 1997-09-10 | 2000-10-04 | 中国石油化工总公司 | 低碳烯烃直接水合连续生产低碳醇的方法 |
CN111954672B (zh) * | 2018-05-11 | 2023-09-01 | 昱展新药生技股份有限公司 | 丁丙诺啡衍生物的长效注射制剂及结晶形式 |
AU2019416507A1 (en) * | 2018-12-27 | 2021-06-03 | Alar Pharmaceuticals Inc. | Naltrexone injectable sustained release formulation |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001015699A1 (en) | 1999-08-27 | 2001-03-08 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
ATE444296T1 (de) | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
TWI226830B (en) * | 2002-11-12 | 2005-01-21 | Chi Mei Foundation Medical Ct | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgesic pharmaceutical compositions |
CN1263760C (zh) * | 2002-11-12 | 2006-07-12 | 财团法人奇美医院 | 新颖的丁丙诺啡酯衍生物及其制备方法,以及长效作用镇痛药学组合物 |
EP1422230B1 (en) * | 2002-11-25 | 2007-12-26 | Chi Mei Foundation Medical Center | Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions |
ES2309766T3 (es) | 2004-06-04 | 2008-12-16 | Camurus Ab | Formulaciones liquidas de liberacion lenta. |
KR20080071185A (ko) * | 2005-11-21 | 2008-08-01 | 쉐링-프라우 리미티드 | 부프레노르핀을 포함하는 약제학적 조성물 |
GB0606124D0 (en) * | 2006-03-28 | 2006-05-03 | Reckitt Benckiser Healthcare | Buprenorphine derivatives and uses thereof |
WO2008036980A1 (en) * | 2006-09-22 | 2008-03-27 | Alltranz Inc. | Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof |
US20090181068A1 (en) * | 2008-01-14 | 2009-07-16 | Dunn Richard L | Low Viscosity Liquid Polymeric Delivery System |
GB2513060B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
GB2513267B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
FR2975912B1 (fr) * | 2011-05-30 | 2013-06-14 | Flamel Tech Sa | Composition a liberation controlee de buprenorphine |
US9393211B2 (en) | 2013-03-15 | 2016-07-19 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
GB201419091D0 (en) * | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
-
2017
- 2017-09-12 SG SG11201901294QA patent/SG11201901294QA/en unknown
- 2017-09-12 HR HRP20230062TT patent/HRP20230062T8/hr unknown
- 2017-09-12 US US16/098,864 patent/US10744132B2/en active Active
- 2017-09-12 CN CN201780055635.3A patent/CN109789137B/zh active Active
- 2017-09-12 AU AU2017325910A patent/AU2017325910B2/en active Active
- 2017-09-12 PT PT178502456T patent/PT3512518T/pt unknown
- 2017-09-12 LT LTEPPCT/CN2017/101327T patent/LT3512518T/lt unknown
- 2017-09-12 RS RS20230034A patent/RS63894B1/sr unknown
- 2017-09-12 PE PE2019000487A patent/PE20190707A1/es unknown
- 2017-09-12 DK DK17850245.6T patent/DK3512518T3/da active
- 2017-09-12 PL PL17850245.6T patent/PL3512518T3/pl unknown
- 2017-09-12 TW TW106131215A patent/TWI743193B/zh active
- 2017-09-12 FI FIEP17850245.6T patent/FI3512518T3/fi active
- 2017-09-12 RU RU2019102895A patent/RU2747306C2/ru active
- 2017-09-12 BR BR112019004923A patent/BR112019004923A2/pt active Search and Examination
- 2017-09-12 ES ES17850245T patent/ES2934721T3/es active Active
- 2017-09-12 SI SI201731295T patent/SI3512518T1/sl unknown
- 2017-09-12 HU HUE17850245A patent/HUE060906T2/hu unknown
- 2017-09-12 MY MYPI2019000910A patent/MY196269A/en unknown
- 2017-09-12 CA CA3033046A patent/CA3033046C/en active Active
- 2017-09-12 EP EP17850245.6A patent/EP3512518B1/en active Active
- 2017-09-12 JP JP2019535434A patent/JP6929367B2/ja active Active
- 2017-09-12 KR KR1020197009185A patent/KR102244500B1/ko active IP Right Grant
- 2017-09-12 WO PCT/CN2017/101327 patent/WO2018050043A1/en unknown
- 2017-09-12 MX MX2019002675A patent/MX2019002675A/es active IP Right Grant
- 2017-09-13 AR ARP170102519A patent/AR110468A1/es unknown
-
2019
- 2019-02-12 ZA ZA2019/00890A patent/ZA201900890B/en unknown
- 2019-03-01 PH PH12019500466A patent/PH12019500466A1/en unknown
- 2019-03-12 CL CL2019000624A patent/CL2019000624A1/es unknown
- 2019-04-11 CO CONC2019/0003632A patent/CO2019003632A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122838T1 (el) | Τοπικες συνθεσεις οι οποιες περιλαμβανουν φιπρονιλη και περμεθρινη και μεθοδοι χρησης | |
PE20180690A1 (es) | Composiciones de acido obeticolico y metodos de uso | |
CO2018010748A2 (es) | Agentes antivirales contra la hepatitis b | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
AR110468A1 (es) | Formulaciones de buprenorfina de liberación sostenida y método de tratamiento | |
CR20120414A (es) | Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos para utilizar los mismos | |
PE20181093A1 (es) | Compuestos heterociclicos y usos de los mismos | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
PE20160665A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x | |
CO2020002980A2 (es) | Agentes antivirales contra la hepatitis b. | |
CO6231001A2 (es) | Estabilizacion de vitamina b12 | |
UY32793A (es) | Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos | |
ECSP12012104A (es) | Inhibidores de virus flaviviridae | |
CR20120418A (es) | Inhibidores de virus flaviviridae | |
AR089004A1 (es) | Composiciones farmaceuticas inyectables, metodo, uso | |
PE20200698A1 (es) | Gel que comprende clorhexidina | |
CO2019004190A2 (es) | Formulaciones liposomales para uso en el tratamiento del cáncer | |
SV2011003907A (es) | Composiciones antimicrobianas | |
AR064425A1 (es) | Composiciones farmaceuticas y metodo para el tratamiento de la inflamacion en el ganado y en otros animales | |
AR072223A1 (es) | Composiciones transdermicas farmaceuticas y metodo para tratar la inflamacion en el ganado vacuno | |
PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
BR112017025395A2 (pt) | formulações farmacêuticas para liberação prolongada de sebacoil éster de dinalbufina | |
AR099751A1 (es) | Formulaciones basadas en melatonina para administración parenteral | |
EA201591910A1 (ru) | Стабильный раствор бромфенака |